Festel, Gunter

Research Interests | Publications | Curriculum Vitae| Other Activities

 

Besides his various business activities, Gunter Festel is part-time member of the faculty «Management, Technology, and Economics» (D-MTEC). In this function, he has built up the Start-Up Research Group within the chair of Prof. Dr. Roman Boutellier.

Gunter Festel is founder and CEO of the advisory and investment firm FESTEL CAPITAL (www.festel.com). His company specializes in the commercialisation of technologies in the areas of energy, environment, health, materials and nutrition. He started the Founding Angels Initiative (www.founding-angels.com) and has co-founded, as a Founding Angel, various biotechnology start-ups in Germany and Switzerland.

Prior to that, he was head of the consulting business for the chemical and healthcare industry with Arthur D. Little in Zurich and a consultant with McKinsey. He started his career with Bayer, where he held various management positions in R&D and marketing. Gunter Festel has a Master in both chemistry and economics, a PhD in natural sciences, a PhD in management & economics as well as an Executive Master and a Master of Advanced Studies in Corporate Finance.

Gunter Festel is a member of various advisory boards, consultant to the OECD and reviewer for the German Federal Ministry for Education and Research (BMBF) within various governmental programmes. He is author of numerous books and more than 250 publications on various topics such as industry trends in the chemical and pharma industries, corporate finance, innovation management, biotechnology, nanotechnology and polymer chemistry/physics.

Research Interests

Gunter Festel and the Start-up Research Group investigate 1) strategic, operational and financial aspects of start-ups/spin-offs, 2) the Founding Angels concept to foster the foundation of start-ups/spin-offs and 3) alternative financing strategies to realise innovations. His sectoral focus is on the chemical, pharmaceutical, biotech, medical devices and energy industries, and his technological focus on biotechnology, nanotechnology and energy technologies.

1) Start-ups and Spin-offs
As a rule, a gap exists between academic research and the commercialisation of the research results, which, in innovation processes, represents a serious barrier. Start-ups/spin-offs can bridge this gap as they can enable the fast transfer of research results into products due to their flexibility and efficiency. As a catalyst for the commercial success of new innovative technologies, they are of more and more importance for high-tech areas. Furthermore, examples from different industries show that established companies can increase their innovation by spinning-off selected businesses. Within the research work the mechanisms and dynamics of academic and corporate start-ups/spin-offs are investigated to understand success factors and best practice approaches.

2) Founding Angels Concept
Business Angels and Venture Capital companies are normally focused on already founded companies, so they are unable to fill the gap between academic research and market success should insufficient start-ups be founded. Founding Angels stand for an innovative business model which could help as driving force for the foundation of new start-up companies. Scientists are supported financially and operationally from the generation of business ideas to the building up of start-ups. This business model is already being successfully implemented in the UK and the US mostly in the area of nanotechnology, and meanwhile there are also some biotechnology examples in Germany and Switzerland. These examples are analysed to understand and further develop the Founding Angels business model (see www.founding-angels.com for more information).

3) Financing of Innovation
More and more companies have insufficient capital for innovations and have to realise that they need to find other ways of financing to strengthen innovation. There are some alternative financial sources for companies like mezzanine financing, project financing and private equity financing but practical aspects are not sufficiently understood and, therefore, not used by most companies. The research work covers a broad range of examples like the financing of pharmaceutical development projects by specialised investment funds, the realisation of buy-and-build strategies of private equity owned companies or alternative financing models of industrial infrastructures in industrial parks in the chemical and lifescience industry.

Publications (selection)

Chemical Industry - General Trends

• G. Festel, Zunehmende Shareholder Value-Orientierung in der chemischen Industrie, Chemie & Wirtschaft, Vol. 1, No. 1, February 2002, p. 35-45
• P. Haug, C. Fischer-Barocci, G. Festel, Strukturelle Anpassungen der Chemieindustrie im Fokus des 6. Workshops bei Clariant in Frankfurt, Chemie & Wirtschaft, Vol. 1, No. 2, May 2002, p. 4-7
• G. Festel, Strukturwandel in der chemischen Industrie Deutschlands, Chemie & Wirtschaft, Vol. 1, No. 2, May 2002, p. 43-53
• P. Haug, C. Fischer-Barocci, G. Festel, Strukturelle Änderungen der chemischen Industrie als Schwerpunkt des 6. Workshops bei Clariant in Frankfurt, Nachrichten aus der Chemie, Vol. 50, No. 9, September 2002, p. 1026-1027
• G. Festel, Historical Evolution and Actual Trends of the Global Chemical Industry, Chemie & Wirtschaft, Vol. 2, No. 1, February 2003, p. 27-34
• G. Festel, Struktureller Wandel in der Chemieindustrie, Chemie & Wirtschaft, Vol. 2, No. 3, August 2003, p. 76-92
• G. Festel, Shareholder Value as Driving Force for Transformations of Chemical Companies, Chemie & Wirtschaft, Vol. 2, No. 4, November 2003, p. 26-42
• G. Festel, Die Chemieindustrie in 10 Jahren, Chemie & Wirtschaft, Vol. 2, No. 4, November 2003, p. 42-49
• G. Festel, Die Wege der drei Großen, Nachrichten aus der Chemie, Vol. 51, No. 12, December 2003, p. 1272-1274
• G. Festel, Degussa strukturiert um, Nachrichten aus der Chemie, Vol. 51, No. 12, December 2003, p. 1275
• G. Festel, Wandel in Chemie und Pharma - Was macht die Schweiz anders?, Nachrichten aus der Chemie, Vol. 52, No. 1, January 2004, p. 45-47
• G. Festel, Die chemische Industrie in Deutschland, Chemie & Wirtschaft, Vol. 3, No. 2, May 2004, p. 17-20
• G. Festel, The Impact of Lifesciences on the Chemical Industry, Chemie & Wirtschaft, Vol. 3, No. 2, May 2004, p. 21-27
• G. Festel, Wandel der Chemie- und Pharmaindustrie in der Schweiz - Ein Vergleich mit Deutschland, Chemie & Wirtschaft, Vol. 3, No. 3, August 2004, p. 31-36

Chemical Industry - Private Equity

• P. Haug, G. Festel, M&A und Buyouts in der chemischen Industrie, Nachrichten aus der Chemie, Vol. 50, No. 1, January 2002, p. 82-83
• K. Alberti, G. Festel, A. Riemann, S. Rüdiger, Buyouts in der chemischen Industrie - Chance für etablierte Chemieunternehmen?, Chemische Rundschau, Vol. 55, No. 6, 22nd March 2002, p. 6
• G. Festel, S. Rüdiger, K. Alberti, Buyouts in der chemischen Industrie - ein richtungsweisender Trend?, Chemanager, No. 7/2002, 15th April 2002, p. 7
• K. Alberti, G. Festel, S. Rüdiger, A. Riemann, Acquire with success - Buyouts have grown from an exotic exception to a widely accepted alternative in the current round of chemical and pharmaceutical restructuring, Chemistry & Industry, No. 8, 15th April 2002, p. 13
• G. Festel, S. Rüdiger, K. Alberti, Buyouts in der Chemie, Nachrichten aus der Chemie, Vol. 50, No. 5, May 2002, p. 621-622
• G. Festel, K. Alberti, Buyouts in der kunststofferzeugenden und -verarbeitenden Industrie, Nachrichten aus der Chemie, Vol. 51, No. 2, February 2003, p. 211-212
• G. Festel, M. Piduhn, Buyouts in der Fein- und Spezialitätenchemie, Nachrichten aus der Chemie, Vol. 51, No. 3, March 2003, p. 376-378
• K. Alberti, G. Festel, Exits bei Chemie-Buyouts, Nachrichten aus der Chemie, Vol. 51, No. 5, May 2003, p. 560-561
• G. Festel, Aktuelle Trends und innovative Kooperationsmodelle zwischen Industrie und Finanzinvestoren bei Management Buyouts am Beispiel der Chemie- und Pharmaindustrie, M&A Review, July 2003, p. 316-321
• G. Festel, M&A in der Chemieindustrie - Finanzinvestors Liebling: Was Private-Equity-Häuser an der Chemiebranche finden, Finance Magazin, July/August 2003, p. 52-53
• G. Festel, Buyouts – Aktueller Trend in Chemie und Pharma, Nachrichten aus der Chemie, Vol. 51, No. 9, September 2003, p. 944-945
• G. Festel, Buyouts in der Chemieindustrie, Venture Capital Magazin, No. 11, November 2003, p. 20-21
• G. Festel, Internal Buyouts in Drug Discovery, Chemistry & Industry, No. 4, 1st Februar 2004, p. 18-19
• G. Festel, A. Mader, Rubber banding, European Chemical News, 2nd February 2004, p. 19-20
• G. Festel, MBO im Mittelstand: Alternative für die Unternehmensnachfolge, Information für den GmbH-Geschäftsführer, No. 19/2004, 6th May 2004, p. 1-3
• G. Festel, Trendwende bei M&A, Chemische Rundschau, Vol. 57, No. 5, 18th May 2004, p. 18-20
• G. Festel, Lückenbüßer? - Finanzinvestoren begeistern sich für die Chemieindustrie, Finance Magazin, April 2008, p. 68-69

Chemical Industry - Trends in China

• G. Festel, China rüstet zum Angriff, Chemische Rundschau, 57. Vol., No. 9, 28. September 2004, p. 20-22
• G. Festel, C.-M. Bell, Forschung und Entwicklung in China, Nachrichten aus der Chemie, Vol. 52, No. 10, October 2004, p. 1063-1064
• G. Festel, Riesenmarkt und hohe Kompetenz - China lockt westliche Unternehmen, Chemische Rundschau, 57. Vol., No. 11, 23. November 2004, p. 18-19
• G. Festel, C.-M. Bell, H. Müller, Konkurrenz aus China bedroht die europäische Chemieindustrie, Nachrichten aus der Chemie, Vol. 53, No. 1, January 2005, p. 38-39
• G. Festel, Pharma R&D in China, Screening, No. 6, May 2005, p. 10-11
• G. Festel, Research with a Chinese slant, European Chemical News, July 2005, p. 18
• G. Festel, H. Müller, Chinas chemische Industrie, Nachrichten aus der Chemie, Vol. 53, No. 7/8, July/August 2005, 791-793
• G. Festel, Bedrohung der europäischen Chemieindustrie durch China, Chemie & Wirtschaft, Vol. 4, No. 2, December 2005, p. 34-40
• G. Festel, Investieren in China, Nachrichten aus der Chemie, Vol. 54, No. 1, January 2006, 36-37
• G. Festel, Unchallenged attractiveness - Investments in China from the viewpoint of foreign chemical companies, Achema Worldwide News, No. 2, November 2006, p. 8-9
• G. Festel, Investing in Production - Investments from the Viewpoint of Foreign Companies, Business Forum China, No. 6/06, November/December 2006, p. 18-19

Pharma Industry - R&D Trends

• M. Falk, G. Festel, Die Zukunft der Pharmaindustrie - Bedeutung der Chemie in der Arzneimittelforschung, Diskussion forum on 29th August 2002 at Speedel in Basel, Chemie & Wirtschaft, Vol. 1, No. 3, August 2002, p. 6-10
• G. Festel, M. Falk, U. Hofmeier, Outsourcing bei der Wirkstoffentwicklung in der Pharmaindustrie am Beispiel von Synthesedienstleistungen, Chemie & Wirtschaft, Vol. 1, No. 3, August 2002, p. 11-16
• M. Falk, G. Festel, New ways to buy in chemistry, Scrip Magazine, October 2002, p. 58-59
• G. Festel, M. Falk, U. Hofmeier, Paradigmenwechsel beim Outsourcing von F&E - Outsourcing von Synthesedienstleistungen, Chemanager, No. 22/2002, p. 88-89
• G. Festel, M. Falk, U. Hofmeier, Syntheseforschung als Dienstleistung, Nachrichten aus der Chemie, Vol. 50, No. 12, December 2002, p. 1377-1378
• M. Falk, J. Luithle, G. Festel, Die Zukunft der Pharmaindustrie - Bedeutung der Chemie in der Arzneimittelforschung, Nachrichten aus der Chemie, Vol. 50, No. 12, December 2002, p. 1401-1402
• G. Festel, M. Falk, U. Hofmeier, Leased competence: A new R&D model in outsourcing chemical synthesis, Chimica Oggi/Chemistry Today - Outsourcing Compendium, Vol. 21, No. 1/2, January/February 2003
• G. Festel, M. Falk, U. Hofmeier, Changement de paradigmes pour l’externalisation en matière de R&D - L’outsourcing de presentations de service de synthèse, BIO Forum France, No. 1, April 2002, p. 14-15
• G. Festel, Drug Substance Outsourcing in the Pharma Industry, Chemie & Wirtschaft, Vol. 2, No. 4, November 2003, p. 14-25
• G. Festel, Steigerung der Innovationskraft von Pharmaunternehmen durch Wissensmanagement, Chemie & Wirtschaft, Vol. 3, No. 1, February 2004, p. 49-54
• G. Festel, Effizienzsteigerung in der Pharma-F+E durch Outsourcing am Beispiel von Syn-thesedienstleistungen, Chemie & Wirtschaft, Vol. 3, No. 1, February 2004, p. 54-60
• G. Festel, Externe Partner kommen immer stärker zum Zug, Chemische Rundschau, 57. Vol., No. 11, 23rd November 2004, p. 20-22
• G. Festel, U. Hofmeier, Outsourcing in der Pharma-Forschung und Entwicklung, in: A. Wullenkord (Eds.), Praxishandbuch Outsourcing, München 2005, p. 173-185

Pharma Industry - Production Trends

• G. Festel, E. Polastro, Dritte arbeiten häufig kostengünstiger - Outsourcing der Wirkstoffproduktion in der Pharmaindustrie, Chemische Rundschau, 55. Vol., No. 13, 28th June 2002, p. 7
• G. Festel, Outsourcing der Wirkstoffproduktion in der Pharmaindustrie, Chemie & Wirtschaft, Vol. 1, No. 3, August 2002, p. 16-21
• G. Festel, M. Falk, Wirkstoffproduktion in der Fremde, Nachrichten aus der Chemie, Vol. 50, No. 10, October 2002, p. 1142-1143

Pharma Industry - Logistics Trends

• G. Festel, H. Götz, Kostendruck bewirkt neue Strukturen in der Healthcare-Logistik, Chemische Rundschau, 57. Vol., No. 1, 27th January 2004, p. 12-13
• G. Festel, H. Götz, Einfluss der Gesundheitsreform auf die Healthcare-Logistik, Logistik für Unternehmen, 18 Vol., No. 3, March 2004, p. 20-21
• G. Festel, H. Götz, Kostendruck bewirkt neue Strukturen in der Healthcare-Logistik, Chemie & Wirtschaft, Vol. 3, No. 2, May 2004, p. 47-52
• G. Festel, H. Götz, Outsourcing der Logistik von Fertigerzeugnissen in der Pharmaindustrie, PharmInd - Die Pharmazeutische Industrie, Vol. 66, No. 10, October 2004, p. 1198-1201

Pharma Industry - Financing Trends

• G. Festel, Finanzmanagement in der Arzneimittelindustrie, in: R. Busse, J. Schreyögg, C. Gericke (Hrsg.), Management im Gesundheitswesen, Heidelberg 2006, p. 260-266
• G. Festel, Finanzierung von Innovationen, Nachrichten aus der Chemie, Vol. 55, No. 11, November 2007, p. 1106-1107
• G. Festel, R. Boutellier, Steigerung der Innovationsfähigkeit bei mittelständischen Pharmaunternehmen durch alternative Finanzierungsmöglichkeiten, PharmInd - Die Pharmazeutische Industrie, Vol. 71, No. 2, February 2009, p. 210-217
• G. Festel, R. Boutellier, Projektorientierte KMU-Finanzierung am Beispiel der Pharmaindustrie, KMU Magazin, Vol. 12, No. 2, March 2009, p. 72-75
• G. Festel, R. Boutellier, Innovationen alternativ finanzieren, Chemische Rundschau, Vol. 62., No. 5, 30th April 2009, p. 13-14

Pharma Industry - Trends in China

• G. Festel, Biotech R&D in China - Opportunities for Foreign Companies?, DIB Nachrichten, No. 9, September 2006
• G. Festel, China targets biotech, ICIS Chemical Business, 18th September 2006, p. 36-37
• G. Festel, On the upswing - Biotechnology in China, Achema Worldwide News, No. 2, November 2006, p. 12-13
• G. Festel, Biotech - Biotechnology Investments in China, Business Forum China, No. 1/07, January/February 2007, p. 72-74
• G. Festel, Biotechnology in China, Journal of International Biotechnology Law, Vol. 4, Issue 3, June 2007, p. 127-130

Pharma Industry - Trends in India

• G. Festel, Pharma Contract Research in India, Nachrichten aus der Chemie, Vol. 55, No. 12, December 2007, p. 1220-1222
• G. Festel, Investing in Indien R&D, Chemistry & Industry, No. 2, 28th January 2008, p. 17-19
• G. Festel, Investing in Indian R&D - New money pouring into research & development in India makes the country an attractive place for innovation, Entrepreneur.com, 28th January 2008
• G. Festel, Let’s go to India - Pharma and Biotech in India, Achema Worldwide News, No. 1, March 2008, p. 12-13
• G. Festel, Indien gewinnt als Standort für Forschung und Wirkstoffproduktion an Bedeutung, Process Online, 7th March 2008
• G. Festel, Verlockendes Indien, Process PharmaTEC, Vol. 14, April 2008, p. 12-13
• G. Festel, Development of the Pharma and Biotech Industry in India with Focus on R&D Activities, Journal of International Biotechnology Law, Vol. 5, Issue 2, April 2008, p. 79-81
• G. Festel, Optimum conditions for growth – Research in India, Chemische Rundschau, Vol. 61, No. 5, 9th Mai 2008, p. 39-44

Biotechnology - Market Trends

• G. Festel, Bio- und Gentechnologie in Deutschland, Nachrichten aus Chemie, Technik und Laboratorium, Vol. 47, No. 3, March 1999, p. 317-319
• G. Festel, J. Knöll, H. Götz, Industrielle Biotechnologie - Wirtschaftlichkeitsfaktor limitiert Marktdurchdringung, Chemische Rundschau, Vol. 56, No. 24, 16th December 2003, p. 13-14
• G. Festel, J. Knöll, H. Götz, H. Zinke, Bio-ways to drugs, European Chemical News, 19th January 2004, p. 22
• G. Festel, J. Knöll, H. Götz, Potential der industriellen Biotechnologie umsetzen, Transkript, Vol. 10, No. 1-2, January 2004, p. 21-22
• G. Festel, J. Knöll, H. Götz, Weisse Biotechnologie: Chemikalien aus dem Fermenter, Nachrichten aus der Chemie, Vol. 52, No. 2, February 2004, p. 166-167
• G. Festel, J. Knöll, H. Götz, H. Zinke, Der Einfluss der Biotechnologie auf Produktionsverfahren in der Chemieindustrie, Chemie Ingenieur Technik, 76, No. 3, March 2004, p. 307-312
• G. Festel, J. Knöll, H. Götz, Industrial Biotech - Influencing Production, Chemistry & Industry, No. 7, 5th April 2004, p. 21-22
• G. Festel, O. Foth, H. Zinke, Getting white to go right, European Chemical News, 23rd May 2005, p. 20-21
• G. Festel, The Impact of Biotechnology on Fine Chemicals, European Biotechnology Science & Industry News, Vol. 4, No. 6-7, June 2005, p. 28-30
• G. Festel, S. Kölle, O. Foth, Demnächst beginnt die Erntezeit, Chemische Rundschau, Vol. 58, No. 9, 20th September 2005, p. 22-23
• G. Festel, S. Kölle, D. Sell, Biopolymers on the way up, European Chemical News, 3rd October 2005, p. 26
• G. Festel, O. Foth, S. Kölle, Kunststoffe, Hydrauliköle, Fasern und Schmiermittel, Nachrichten aus der Chemie, Vol. 53, No. 10, October 2005, p. 1042-1043

Biotechnology - Regulations

• G. Festel, P. Oberender, Der Einfluß des Staates auf innovative Zukunftstechnologien, Wirtschaftsdienst, 79. Vol., No. 1, January 1999, p. 57-64
• G. Festel, Bio- und Gentechnologie in Deutschland, Nachrichten aus Chemie, Technik und Laboratorium, Vol. 47, No. 3, March 1999, p. 317-319
• G. Festel, Wettbewerbsfähigkeit von Bio- und Gentechnologie in Deutschland, Chemie & Wirtschaft, Vol. 1, No. 1, February 2002, p. 46-54
• G. Festel, Gentechnik und Innovation als Wettbewerbsfaktor, Chemie & Wirtschaft, Vol. 1, No. 2, May 2002, p. 29-34
• G. Festel, Gentechnik und stattlicher Regulierungsbedarf, Chemie & Wirtschaft, Vol. 1, No. 2, May 2002, p. 34-43
• G. Festel, Gentechnik und Öffentlichkeit, Chemie & Wirtschaft, Vol. 1, No. 3, August 2002, p. 30-38
• G. Festel, Die Entwicklung des Gentechnik-Gesetzes in Deutschland - Ein Rückblick, Chemie & Wirtschaft, Vol. 3, No. 1, February 2004, p. 28-45

Biotechnology - Financing Trends

• G. Festel, O. Foth, A. Heft, H. Zinke, Weit unter dem Potential - Kapitalspritze erforderlich, Chemische Rundschau, Vol. 58., No. 8, 23rd August 2005, p. 24-25
• G. Festel, Wachstums- und Finanzierungsstrategien von Start-ups im Bereich der industriellen Biotechnologie, M&A Review, November 2005, p. 481-484
• G. Festel, O. Foth, A. Heft, Weisse Biotechnologie - Neue Finanzierungsstrategien, Transkript, 11. Jg., No. 11, November 2005, p. 54
• G. Festel, D. Terzenbach, Wege zum Wachstum, Nachrichten aus der Chemie, Vol. 55, No. 4, April 2007, p. 417-418
• G. Festel, Bedeutung von Start-ups in der industriellen Biotechnologie, Going Public Magazin - Sonderausgabe Biotechnologie 2007, September 2007, p. 104-105
• G. Festel, E. Boles, Vom Forschungsprojekt zum eigenen Unternehmen, Nachrichten aus der Chemie, Vol. 56, No. 7/8, July 2008, p. 843-844
• G. Festel, „Entwicklungshilfe“ für die industrielle Biotechnologie, Going Public Magazin - Sonderausgabe Biotechnologie 2008, September 2008, p. 98-99
• G. Festel, Founding Angels stehen Pate bei der Gründung von Biotech-Start-ups, Chemische Rundschau, Vol. 61., No. 9, 12th September 2008, p. 20-21
• G. Festel, R. Boutellier, Finanzierung von Innovationen - KMU-Finanzierung am Beispiel der industriellen Biotechnologie, KMU-Magazin, Vol. 11., No. 9, November 2008, p. 96-99
• G. Festel, Mezzanine als Finanzierungsoption im Bereich der industriellen Biotechnologie, Chemie & Wirtschaft, Vol. 8, No. 1, May 2009, p. 9-15
• G. Festel, Founding Angel – Unternehmensgründung in Serie, Biospektrum, Vol. 15, No. 3, May 2009, p. 327
• G. Festel, T. Niemann, Investieren in industrielle Biotechnologie – Chancen in Zeiten der Finanz- und Wirtschaftskrise, Going Public Magazin, July 2009, p. 60-61
• G. Festel, Zielgerichtete Umsetzung von Gründungsprojekten am Beispiel eines Biotech-Start-ups, in: K. Dautzenberg, G. Reger (Eds.), Risikobewertung und Finanzierung von technologieorientierten Gründerinnen und Gründern, Eul Verlag, Lohmar 2009, p. 105-111

Nanotechnology - Market Trends

• G. Festel, G. Klatt, R. Iden, W. Luther, Damit aus der Forschung Produkte für den Markt entstehen, Nachrichten aus der Chemie, Vol. 54, No. 2, Februar 2006, p. 137-139
• W. Luther, G. Bachmann, G. Festel, G. Klatt, A. Zweck, Kommerzialisierung der Nanotechnologie, VDI Technologiezentrum, Zukünftige Technologien No. 65, June 2006
• G. Festel, Kommerzialisierungschancen der Nanotechnologie in Deutschland, Venture Capital Magazin, Tech-Guide 2006, July 2006, p. 76-78
• G. Festel, R. Boutellier, Start-ups zur Steigerung der Innovationsfähigkeit - Bedeutung und Handlungsempfehlungen am Beispiel der Nanotechnologie, Wissenschaftsmanagement, No. 1, January/February 2008, p. 19-25

Nanotechnology - Financing Trends

• G. Festel, R. Boutellier, Start-ups zur Steigerung der Innovationsfähigkeit - Bedeutung und Handlungsempfehlung am Beispiel der Nanotechnologie, Wissenschaftsmanagement, Vol. 14, No. 1, January/February 2008, p. 19-25
• G. Festel, Neues Modell schliesst Lücke, Chemische Rundschau, Vol. 61, No. 3, 17th March 2008, p. 26-28
• G. Festel, R. Boutellier, Investoren übersehen Nanotechnologie, Founding Angels können auch im deutschsprachigen Raum die Innovationsfähigkeit steigern, Venture Capital Magazin / Tech Guide 2008, July 2008, p. 68-69
• G. Festel, R. Boutellier, Investoren übersehen Nanotechnologie - Founding Angels können auch im deutschsprachigen Raum die Innovationsfähigkeit steigern, Venture Capital Magazin / Tech-Guide 2008, July 2008, p. 68-69
• G. Festel, R. Boutellier, Founding Angels als innovatives Geschäftsmodell, IO New Management, No. 7/8, July/August 2008, p. 37-39
• G. Festel, Bedeutung von „Founding Angels“ am Beispiel der Bio- und Nanotechnologie, Chemie & Wirtschaft, Vol. 7, No. 1, August 2008, p. 48-53

Innovation Management - General Trends

• G. Festel, Linking R&D and marketing, Chemtech, Vol. 29, No. 4, April 1999, p. 7-10
• G. Festel, Innovationsmanagement – von der Idee zum Produkt, Nachrichten aus Chemie, Technik und Laboratorium, Vol. 47, No. 6, June 1999, p. 686-688
• G. Festel, F+E-Management in innovativen Unternehmen, IO Management, Vol. 1999, No. 7/8, p. 62
• G. Festel, K. Alberti, Innovation in der Chemie- und Pharmaindustrie – Neue Ansätze zur Steigerung der Innovationsfähigkeit, Nachrichten aus der Chemie, Vol. 51, No. 9, September 2003, p. 981-982

Innovation Management - R&D Spin offs

• G. Festel, Verheisst eine Abspaltung mehr Innovationskraft?, Chemische Rundschau, Vol. 57., No. 2, 24th February 2004, p. 12-13
• G. Festel, Auszug der Hexenküchen - F+E-Spin-offs in der Chemie-, Pharma- und Biotechindustrie, Finance Magazin, April 2004, p. 30-31
• G. Festel, Corporate FuE-Spin-offs in der Chemie-, Pharma- und Biotech-Industrie, M&A Review, May 2004, p. 219-222
• G. Festel, FuE durch Spin-offs flexibilisieren, Nachrichten aus der Chemie, Vol. 52, No. 7/8, July 2004, p. 819-820
• G. Festel, Flexibilisierung der Pharmaforschung durch MBOs – Möglichkeit zur schnellen Kommerzialisierung von FuE-Ergebnissen, Venture Capital Magazin - Sonderausgabe Buyouts, No. 7, July 2004, p. 38-39
• G. Festel, S. Kölle, Stimulation of innovation by R&D spin-offs, BioWorld Europe, Vol. 1, March 2005, p. 32-33
• G. Festel, R. Boutellier, Founding angels as a driving force for the creation of new high-tech start-up companies, The R&D Management Conference 2008, Ottawa, 20. Juni 2008
• G. Festel, R. Boutellier, Founding Angels als innovatives Geschäftsmodell, IO New Management, No. 7/8, July/August 2008, p. 37-39
• G. Festel, R. Boutellier, Corporate FuE-Spin-offs zur steigerung der Innovationsfähigkeit, Wissenschaftsmanagement, Vol. 15, No. 1, January/February 2009, p. 21-27

Curriculum Vitae

Other Activities

Teaching Activities

• Lecturer at the ETH Zurich in the Department of Management, Technology and Economics: Course on start-ups and venture capital (within the MAS MTEC programme)

• Lecturer at the National University of Singapore at the Faculty of Sciece: Course on entrepreneurship and start-ups

Consulting/Reviewer Activities

• Consultant for the Organisation for Economic Co-operation and Development (OECD)

• Reviewer for the German Federal Ministry for Education and Research (BMBF) within various governmental programmes

• Reviewer of different business plan competitions (e.g. Science4Life)

• Reviewer for various scientific journals (e.g. Chemical Engineering Research and Design, Chemie Ingenieur Technik, CLEAN, Technovation)

Board Memberships

• Autodisplay Biotech: Supervisory board member

• China Association for Management of Technology (CAMOT): Founding member and Member of the Executive Council

• German Chemical Society (GDCh) Association for Chemistry & Economics (GDCh VCW): Co-founder, former Chairman and advisory board member

• Zurich University of Applied Sciences (ZHAW): Advisory board member of the Institute for Chemisty and Biological Chemistry

Other Memberships

• German Society for Petroleum and Coal Science and Technology (DGMK): Member of the division Coal Processing

• Licensing Executives Society (LES): Member of LES International (LESI) and LES Germany

• Society for Chemical Engineering and Biotechnology (Dechema): Personal member

• Swiss Chemical Society (SCG): Member of the division Medical Chemistry